Accepted Manuscript

Discovery of novel Dengue virus entry inhibitors via a structure-based approach

Emilse S. Leal, M. Gabriela Aucar, Leopoldo G. Gebhard, Nestor G. Iglesias, María J. Pascual, Juan J. Casal, Andrea V. Gamarnik, Claudio N. Cavasotto, Mariela Bollini

PII:	S0960-894X(17)30653-4			
DOI:	http://dx.doi.org/10.1016/j.bmc1.2017.06.049			
Reference:	BMCL 25083			
To appear in:	Bioorganic & Medicinal Chemistry Letters			
Received Date:	19 May 2017			
Revised Date:	15 June 2017			
Accepted Date:	19 June 2017			



Please cite this article as: Leal, E.S., Aucar, M.G., Gebhard, L.G., Iglesias, N.G., Pascual, M.J., Casal, J.J., Gamarnik, A.V., Cavasotto, C.N., Bollini, M., Discovery of novel Dengue virus entry inhibitors via a structure-based approach, *Bioorganic & Medicinal Chemistry Letters* (2017), doi: http://dx.doi.org/10.1016/j.bmcl.2017.06.049

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Graphical Abstract

To create your abstract, type over the instructions in the template box below. Fonts or abstract dimensions should not be changed or altered.





Bioorganic & Medicinal Chemistry Letters

Discovery of novel Dengue virus entry inhibitors via a structure-based approach

Emilse S. Leal^{a, ‡}, M. Gabriela Aucar^{b,c, ‡}, Leopoldo G. Gebhard^d, Nestor G. Iglesias^d, María J. Pascual^e, Juan J. Casal^a, Andrea V. Gamarnik^d, Claudio N. Cavasotto^{b,*} and Mariela Bollini^{a,*}

^a Laboratorio de Química Medicinal, Centro de Investigaciones en Bionanociencias (CIBION)-CONICET, Godoy Cruz 2390, Ciudad de Buenos Aires, Argentina.

^b Laboratory of Computational Chemistry and Drug Design, Instituto de Investigación en Biomedicina de Buenos Aires (IBioBA) - CONICET - Partner Institute of the Max Planck Society, Godoy Cruz 2390, Ciudad de Buenos Aires, Argentina.

^c Instituto de Modelado e Innovación Tecnológica, CONICET, and Departamento de Fisica, FCENA-UNNE, Avda. Libertad 5460, Corrientes, Argentina. ^d Fundación Instituto Leloir-CONICET, Av. Patricias Argentinas 435, Ciudad de Buenos Aires, Argentina.

^e Instituto de Investigaciones Biotecnológicas, Universidad Nacional de San Martín, CONICET, Av. 25 de Mayo y Francia, San Martín, Prov. de Buenos Aires, Areentina.

ARTICLE INFO

ABSTRACT

Article history: Received Revised Accepted Available online	Dengue is a mosquito-borne virus that has become a major public health concern worldwide in recent years. However, the current treatment for dengue disease is only supportive therapy, and no specific antivirals are available to control the infections. Therefore, the need for safe and effective antiviral drugs against this virus is of utmost importance. Entry of the dengue virus (DENV) into a host cell is mediated by its major envelope protein, <i>E</i> . The crystal structure of the <i>E</i> protein reveals a hydrophobic pocket occupied by the detergent n-octyl-β-D-glucoside (β-QG)
Keywords: Keyword_1 Envelope protein, Keyword_2 Structure-based drug design, Keyword_3 Virtual screening, Keyword_4 Anti-dengue drugs Keyword_5 Molecular dynamics	If protein receive a hydrophole power occupied by the decirpt in occyr p <i>B</i> proteins a hydrophole power of the low-pH-triggered conformational rearrangement required for fusion. Thus, the <i>E</i> protein is an attractive target for the development of antiviral agents. In this work, we performed prospective docking-based virtual screening to identify small molecules that likely bind to the β -OG binding site. Twenty-three structurally different compounds were identified and two of them had an EC ₅₀ value in the low micromolar range. In particular, compound 2 (EC ₅₀ = 3.1 μ M) showed marked antiviral activity with a good therapeutic index. Molecular dynamics simulations were used in an attempt to characterize the interaction of 2 with protein <i>E</i> , thus paving the way for future ligand optimization endeavors. These studies highlight the possibility of using a new class of DENV inhibitors against Dengue 2009 Elsevier Ltd. All rights reserved.

Dengue virus (DENV) is the most prevalent mosquito-borne viral pathogen and has become a major public health concern worldwide. Presently, dengue is endemic in 112 countries around the world.¹ Mostly in tropical and subtropical areas, each year 50–100 million individuals are infected with DENV resulting in nearly 500,000 severe illnesses and 25,000 deaths.^{2.3} Four distinct serotypes (DENV1-4) of the virus are the major contributors in circulation of DENV in the world population.⁴ Although the number of dengue cases increases every year, there are no approved therapeutics available for the treatment of these infections.

DENV belongs to the flavivirus genus of the *Flaviviridae* family of positive-sense single-stranded RNA viruses.^{5,6} The RNA genome encodes ten proteins; three of them (the so-called **Capsid**, Membrane and Envelope proteins) are structural proteins

that are present in the infectious virus particle, composed of a lipid bilayer that anchors envelope and membrane proteins, surrounding the viral RNA complexed with the capsid protein. The other seven are nonstructural proteins (i.e.; NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) involved in amplifying the viral genome once the virus reaches the cytoplasm of the cell.⁷ During viral morphogenesis, the capsid protein recruits the viral RNA genome on the cytosolic face of the endoplasmic reticulum (ER), and the assembled nucleocapsid buds into the ER lumen acquiring a coat that contains the Envelope (*E*) glycoprotein and the precursor Membrane protein, prM. Then, the particle passes through the secretory pathway, where a furin-like protease cleaves prM to M in a late trans-Golgi compartment.⁸ The cleavage releases a constraint on the *E* glycoprotein and primes the particle for low-pH-triggered membrane fusion. The *E*

* Corresponding Author mariela.bollini@cibion.conicet.gov.ar; cnc@cavasotto-lab.net, ccavasotto@ibioba-mpsp-conicet.gov.ar.

[‡]These authors equally contributed to this work.

glycoprotein is a major component of the virion surface and plays an important role in binding to the host receptor, drives viral fusion, and induces immunogenic response in host cell.^{9,10}

The crystal structure of the DENV *E* protein reveals a hydrophobic pocket occupied by the detergent n-octyl- β -D-glucoside (β -OG) lying at a hinge region between domains I and II of the protein, which is important for the low-pH-triggered conformational rearrangement required for membrane fusogenic activity. Therefore, the β -OG binding site was proposed as an appropriate target for developing small-molecule inhibitors of virus-host membrane fusion process.^{11–14}

The available structural data of the DENV E opened up the possibility to identify antiviral agents interfering with the early steps of DENV infection. In this work, we undertook a multistep hierarchical prospective structural-based virtual screening (SBVS) strategy targeting the β -OG hydrophobic binding site of the solved crystal structure of protein E (PDB code: 10KE) to identify novel entry inhibitors with improved potency and efficacy against E. Docking-based virtual screening was performed using approximately 110000 small-molecules from the Maybridge database using the ICM software, which proved successful for finding hits on several other targets.¹⁵⁻¹⁸ The screening protocol began with an ADME filter,¹⁹ in order to retain only potentially non-toxic and druggable molecules, which were subjected to two independent high-throughput docking (HTD) screenings, where the best score per molecule was kept.² The top ranked 500 molecules were manually inspected using the following criteria: (i) docking pose overlapping with the cocrystallized β-OG ligand, (ii) interaction with binding site amino acids, (iii) scaffold diversity, (iv) commercial availability, and (v) synthetic tractability for potential modifications. All molecules containing unwanted structural features were removed such as those with readily hydrolizable and/or highly electrophilic functional groups. Finally, 23 compounds were taken into consideration for in vitro studies (Scheme S1, Supplementary Information) and were either purchased or synthesized. In particular, compound 2 was prepared and the synthetic route is shown in Scheme 1. The quinazoline ring was installed by condensing aniline 6 with formamide at 150 °C. Heating of compound 7 in excess of thionyl chloride afforded 4-chloro quinazoline 8. The nucleophilic displacement of chlorine in compound 8 by 2-amino-2-pyridinol proceeded in the presence of Cs₂CO₃ in DMF at 100 °C in a good yield, and produced the intermediate 9. Finally, the target compound 2 was obtained by amidation with 5-(pyridin-2-yl)thiophene-2-carboxylic acid BOP mediated by [1-benzotriazolyl-oxytris-(dimethylamino)phosphonium-hexafluoro-phosphate] as coupling reagent (Scheme 1).



Scheme 1. Synthetic Route for the Preparation of compound 2 Reagents and conditions (a) Formamide, 150 °C; (b) SOCl₂, reflux, 8 h; (c) 5-

aminopyridin-2-ol, Cs₂CO₃, DMF, 100 °C, 24 h; (d) 5-(Pyridin-2-yl)thiophene-2-carboxylic acid, BOP, DIPEA, rt, overnight.

The identities of the purchased compounds and compound 2 were verified by NMR and mass spectrometry, and the purity was found to be at least 95% by HPLC



Figure 1. Chemical structures of novel anti-dengue inhibitors.

Antiviral activity was next assessed using a reporter DENV assay based on the measurement of luciferase expression from a recombinant fully functional virus bearing a luciferase coding sequence in the context of the viral genome.^{21,22} After infection of cells in culture with the reporter DENV, luciferase activity first peaks at 8 hours as a result of translation of the incoming genomes, reflecting virus entry into the host cells. At 24 hours post infection, amplification of the genome by the viral polymerase results in an increase in luciferase activity that reflects virus RNA synthesis. Luciferase activity was measured at 8 and 24 hours post infection with the reporter DENV in untreated or treated cells with each of the 23 compounds identified in the virtual screening. The results showed that 5 hits displayed antiviral activity against DENV (Figure 1, Table 1). Compounds 2, 5 and 4 showed marked antiviral inhibition at 8 hours post infection with a good selectivity index. Compounds 1 and 3 showed moderate inhibitory activities and no cytotoxicity was detected at 100 µM. In order to examine the selective antiviral potential of the compounds identified in the virtual screening, we tested these compounds against bovine viral diarrhea virus (BVDV), another member of the Flaviviridae family. None of them demonstrated significant antiviral activity at 50 µM. Taken together, our results suggested that active compounds interfere with early steps of the DENV life cycle, most likely during viral entry.

Table 1. In vitro antiviral effect, cytotoxicity and selectivity of compounds identified (as hits) from the virtual screening.

Compound	$EC_{50}(\mu M)^a$		CC_{50} (IIM) ^b	SI ^c	
	DENV-2 ^d	BVDV	(μινι)		
1	22.7 ± 1.2	>50	>100	>5	
2	3.1 ± 1.1	>50	>100	>32	
3	28.7 ± 1.0	>50	>100	>4	
4	10.8 ± 1.1	>50	>100	>9	
5	5.1 ± 0.9	>50	>100	>20	

^a EC50: 50 % effective concentration ^d8 h post infection

b CC50: 50 % cytotoxic concentration

^c SI: selectivity index

To better characterize the likely interaction of the new ligands with protein *E*, and to explore the role of water molecules (cf. Ref. ²³) (omitted during the docking stage), that might be involved in mediating protein-ligand interaction, we performed 100 ns MD simulation on the most active compound (2). The docked pose of compound 2 was used as the initial conformation. It can be observed that the protein remains stable throughout the simulation (Figure S2). The predicted binding pose of 2 within the *E* protein is displayed in Figure 2a.

The 4-substituted 7-chloro-quinazoline moiety remains exposed to the solvent, while the pyridine attached to it makes contacts with Thr48, Glu49, Leu135, Gln271 and Leu277 (Figure 2b): the system is further stabilized by a dynamic moderate hydrogen bond between the pyridine N and the HN of Ala50, exhibiting an interatomic distance below 2.5 Å during half of the last 50 ns simulation. The O in the amide is intermittently exposed to the solvent through a narrow channel. Several water molecules were found throughout the simulation within the binding site, bridging the interaction of the ligand with the protein. A water molecule with almost 100% occupancy in the last 50 ns makes hydrogen bonds with the N of the terminal pyridine, the hydroxyl group of Tyr137, the carboxylic O of Thr280, and another water molecule, which belongs to a small conserved cluster of three buried water molecules that also interact with the HN of Leu 191 and His282, the carboxylic O of Thr189 and the side chain of His282. A stable π - π interaction between the terminal pyridine ring and Phe193 is also observed throughout the simulation, with an average ring centroid distance of 3.7 Å and an average planes angle of 14° (Figure 1). The 2-(thiophen-2-yl) pyridine moiety is stabilized by hydrophobic contacts with Val130, Leu191, Asp192, Leu207, Ile270, Phe279, and Thr280. It should be stressed that compound 2 overlaps very well with co-crystallized ligand β-OG (Figure 2c). The predicted protein-ligand interaction pattern is in line with recent models.¹

Finally, the pharmacologic characteristics of drug candidates were predicted using QikProp program^{19,24} and are summarized in Table 2. QikProp generates physically relevant descriptors and uses them to perform ADMET predictions. A compound is viewed as potentially problematic if it does not satisfy a "rule-of-three": predicted log S > -6.0, PCaco > 30 nm/s, and maximum number of primary metabolites of six. The most potent compounds reported here compare favorably with all these limits.

In humans, the pH value in stomach is 1-2, while in small intestine it is 5-7. Because compound solubility often depends on pH in solution, it is important to consider different pH buffers. Taking into account the relevance of drug solubility, in vivo absorption and distribution, we tested the in vitro solubility and stability in PBS media for active compounds **2**, **4**, **5** at pH 2.0, 6.4, and 7.4. The solubility data are summarized in Table 3; all compounds showed good solubility and are well inside the range normally observed for oral drugs, 4-4000 μ g/mL²⁴ corresponding to an S of 10⁻² -10⁻⁵ M for compounds with a molecular weight of 400. The ClogP values for the listed compounds are between 3 and 5, which are in the normal range of 0-5 for oral drugs²⁵. The aqueous solubility pattern of the assayed compounds was similar to the predicted solubility.

Compounds 2, 4 and 5 showed low to moderate solubility ranging from 1-10 μ g/mL at pH 7.4. However, these compounds are more soluble at pH 2.0 and pH 6.4.

All the compounds also had a reasonable stability in buffer (>48 h), so no intrinsic stability issues were expected



Figure 2. Predicted interaction of compound **2** within the *E* protein β -OG binding site, extracted from the molecular dynamics simulation. (A) Ribbon representation of protein *E* with compound **2** within the binding site (B). Interaction of **2** with the binding site amino acids and water molecules. For simplicity, backbone nitrogens, carbonyl oxygens are not displayed, except when interacting directly with **2**. Only polar hydrogens are shown. Hydrogen bonds are shown as a line of colored spheres. Color code: **2**, yellow carbons; DENV *E* carbons, white; oxygens, red; nitrogens, blue; sulphur, green; polar hydrogens, dark grey. (C). Superposition of **2** with the β -OG ligand within the binding site. Color code: DENV *E* protein, gray ribbon; β -OG, white carbons.



Figure 3. Plane angles (left panel) and ring centroid distances (right panel) for the π - π interaction between Phe193 and the terminal pyridine moiety of compound **2**

Table 5. Calculated pharmacological characteristics, experimental solubility and stability for active compounds.									
Compound	FC		QlogSc	QPCacod	#met ^e	Aqueous Solubility ^f			PBS
	EC50 (uM)a	QlogPb				µg/mL			stability
	(µm)					рН			(h)
						2.0	6.4	7.4	
2	3.1	4.2	-4.5	785.8	4	12.7	10.1	2.9	>48
4	10.8	3.9	-5.2	520.5	5	48.3	32.1	6.1	>48
5	5.1	3.7	-5.2	1735.6	3	8.2	13.1	1.2	>48

Table 3. Calculated pharmacological characteristics, experimental solubility and stability for active compounds.

^aEC₅₀ (µM) was calculated from dose-response curves by Prism software. The results represent the average of two or more independent experiments.

^b octanol/water partition coefficient (log Po/w)

° aqueous solubility

^dCaco-2 cell permeability

e number of metabolites

^f Experimental solubility at pH 2, 6.4, 7.4. Reference values at pH 6.4 for piroxicam 7.3 µg/mL and efavirenz 68. 3 µg/mL. Values are means of two independent experiments, each running triplicate

Here, we have described a prospective structure-based drug discovery approach to identify novel and potent inhibitors of DENV entry targeting protein E. We performed a multistep hierarchical high-throughput docking of the 110000 Maybridge compounds library, leading to the identification of the quinazoline hit 2 with an EC_{50} of 3 $\mu M,$ and compound 5 with an EC_{50} of 5 μ M, both with a good therapeutic index. Molecular docking for compound 5 and molecular dynamics approaches for 2 predicted strong interactions of both compounds with the key amino acids in the β -OG binding pocket of protein E that are crucial for membrane fusion to deliver the viral genome in the cytoplasm of the infected cell, in agreement with earlier works.13,14 In summary, we have provided novel DENV inhibitors that interfere early during infection, stablishing a platform for the development of new and more potent antivirals against this important human pathogen.

Computational methods

High-throughput docking

All simulations were based on the crystal structure of the ectodomain of the envelope glycoprotein from dengue virus type 2 bound to the detergent n-octyl- β -D-glucoside (β -OG) (PDB 10KE).¹⁰ The molecular system was described in terms of torsional coordinates using the ECEPP/3 force field²⁶ as implemented in the ICM program (version 3.7-2c, MolSoft LLC, La Jolla, CA)^{27,28} The system was prepared in a similar fashion as in earlier works^{29–31} (further details are shown in Supplementary Information).

Molecular dynamics

MD simulations were performed using GROMACS v4.6 package^{32,33} with the Amber99SB force field³⁴ for proteins. Force field parameters for small-molecules were obtained through the AnteChamber PYthon Parser inerface (ACPYPE)³⁵ using the GAFF³⁶ force field. After equilibration, the system was subjected to a 100 ns MD simulation at 310 K (further details are shown in Supplementary Information).

Supporting Information

Supplementary data associated with this article can be found, in the online version.

Acknowledgments

This work has been supported by the Agencia Nacional de Promoción Científica y Tecnológica, Argentina (PICT 2013-0078 and PICT 2014-1884 to MB; PICT 2014-3599 to CNC and MB), CONICET (PIP 2014 11220130100721 to MB and CNC), and FOCEM-Mercosur (COF 03/11).

MB thanks William Jorgensen for providing an academic license for QikProp software. CNC thanks Molsoft LLC for providing an academic license for the ICM program. The authors thank the National System of High Performance Computing (Sistemas Nacionales de Computación de Alto Rendimiento, SNCAD) and the Computational Centre of High Performance Computing (Centro de Computación de Alto Rendimiento, CeCAR) for granting use of their computational resources, and Diego Alvarez for technical help and critical discussion of the manuscript.

References

- 1. http://www.who.int/mediacentre/factsheets/fs117/es/.
- 2. Gubler, D. J. Trends Microbiol. 2002, 10, 100–103.
- Whitehead, S. S.; Blaney, J. E.; Durbin, A. P.; Murphy, B. R. Nat. Rev. Microbiol. 2007, 5, 518–528.
- 4. Ligon, B. L. Semin. Pediatr. Infect. Dis. 2005, 16, 60–65.
- Wichapong, K.; Nueangaudom, A.; Pianwanit, S.; Sippl, W.; Kokpol, S. *Trop. Biomed.* 2013, 30, 388–408.
- Murphy, F. A. In *Encyclopedia of Virology (Third Edition)*; Mahy,
 B. W. J.; Regenmortel, M. H. V. Van, Eds.; Academic Press:
 - Oxford, **2008**; pp. 140–148. Yan, Y.; Li, Y.; Munshi, S.; Sardana, V.; Cole, J. L.; Sardana, M.;
- Yan, Y.; Li, Y.; Munshi, S.; Sardana, V.; Cole, J. L.; Sardana, M.; Kuo, L. C.; Chen, Z.; Steinkuehler, C.; Tomei, L.; Francesco, R. De Protein Sci. 1998, 7, 837–847.
- Plevka, P.; Battisti, A. J.; Junjhon, J.; Winkler, D. C.; Holdaway, H. A.; Keelapang, P.; Sittisombut, N.; Kuhn, R. J.; Steven, A. C.; Rossmann, M. G. *EMBO Rep.* 2011, *12*, 602–606.
- Kuhn, R. J.; Zhang, W.; Rossmann, M. G.; Pletnev, S. V; Corver, J.; Lenches, E.; Jones, C. T.; Mukhopadhyay, S.; Chipman, P. R.; Strauss, E. G.; Baker, T. S.; Strauss, J. H. *Cell* 2002, *108*, 717–725.
- Modis, Y.; Ogata, S.; Clements, D.; Harrison, S. C. Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 6986–6991.
- Poh, M. K.; Yip, A.; Zhang, S.; Priestle, J. P.; Ma, N. L.; Smit, J. M.; Wilschut, J.; Shi, P. Y.; Wenk, M. R.; Schul, W. Antiviral Res. 2009, 84, 260–266.
- Wang, Q. Y.; Patel, S. J.; Vangrevelinghe, E.; Hao, Y. X.; Rao, R.; Jaber, D.; Schul, W.; Gu, F.; Heudi, O.; Ngai, L. M.; Mee, K. P.; Wai, Y. P.; Keller, T. H.; Jacoby, E.; Vasudevan, S. G. Antimicrob. Agents Chemother. 2009, 53, 1823–1831.
- Behnam, M. A. M.; Nitsche, C.; Boldescu, V.; Klein, C. D. J. Med. Chem. 2016.

- Jadav, S. S.; Kaptein, S.; Timiri, A.; De Burghgraeve, T.; Badavath, 14. V. N.; Ganesan, R.; Sinha, B. N.; Neyts, J.; Leyssen, P.; Jayaprakash, V. Bioorg. Med. Chem. Lett. 2015, 25, 1747-1752.
- 15. Cavasotto, C. N.; Orry, A. J. W.; Murgolo, N. J.; Czarniecki, M. F.; Kocsi, S. A.; Hawes, B. E.; O'Neill, K. A.; Hine, H.; Burton, M. S.; Voigt, J. H.; Abagyan, R. A.; Bayne, M. L.; Monsma, F. J.; Monsma Jr., F. J. J. Med. Chem. 2008, 51, 581-588.
- 16. Cavasotto, C. N.; Ortiz, M. A.; Abagyan, R. A.; Piedrafita, F. J. Bioorg. Med. Chem. Lett. 2006, 16, 1969-1974.
- 17. Chan, F.-Y.; Sun, N.; Neves, M. A. C.; Lam, P. C.-H.; Chung, W.-H.; Wong, L.-K.; Chow, H.-Y.; Ma, D.-L.; Chan, P.-H.; Leung, Y.-C.; Chan, T.-H.; Abagyan, R.; Wong, K.-Y. J. Chem. Inf. Model. 2013, 53, 2131-2140.
- 18. Sun, N.; Chan, F.-Y.; Lu, Y.-J.; Neves, M. A. C.; Lui, H.-K.; Wang, Y.; Chow, K.-Y.; Chan, K.-F.; Yan, S.-C.; Leung, Y.-C.; Abagyan, R.; Chan, T.-H.; Wong, K.-Y. PLoS One 2014, 9, e97514.
- Jorgensen, W. L. QikProp, v 3.0; Schrödinger LLC. 19.
- Cavasotto, C. N.; Abagyan, R. A. J. Mol. Biol. 2004, 337, 209-225. 20.
- 21. Mondotte, J. A.; Lozach, P.-Y.; Amara, A.; Gamarnik, A. V J. Virol. 2007, 81, 7136-7148.
- 22. Kato, F.; Hishiki, T. Viruses 2016, 8, 122.
- 23. Spyrakis, F.; Cavasotto, C. N. Arch. Biochem. Biophys. 2015, 583, 105 - 119
- 24. Jorgensen, W. L.; Duffy, E. M. Adv. Drug Deliv. Rev. 2002, 54, 355-366.
- 25. Jorgensen, W. L. Acc. Chem. Res. 2009, 42, 724-733.
- Nemethy, G.; Gibson, K. D.; Palmer, K. A.; Yoon, C. N.; Paterlini, 26. M. G.; Zagari, A.; Rumsey, S.; Scheraga, H. A. J. Phys. Chem. 1992, 96, 6472-6484.
- 27. Abagyan, R.; Totrov, M.; Kuznetsov, D. J. Comput. Chem. 1994, 15, 488-506.
- 28 Neves, M. A. C.; Totrov, M.; Abagyan, R. J. Comput. Aided. Mol. Des. 2012, 26, 675-686.
- 29. Petrov, R. R.; Knight, L.; Chen, S. R.; Wager-Miller, J.; McDaniel, S. W.; Diaz, F.; Barth, F.; Pan, H. L.; Mackie, K.; Cavasotto, C. N.; Diaz, P. Eur. J. Med. Chem. 2013, 69, 881-907.
- 30. He, W.; Elizondo-Riojas, M. A.; Li, X.; Lokesh, G. L.; Somasunderam, A.; Thiviyanathan, V.; Volk, D. E.; Durland, R. H.; Englehardt, J.; Cavasotto, C. N.; Gorenstein, D. G. Biochemistry 2012, 51, 8321-8323.
- 31. Monti, M. C.; Casapullo, A.; Cavasotto, C. N.; Tosco, A.; Dal Piaz, F.; Ziemys, A.; Margarucci, L.; Riccio, R. Chem.-Eur. J. 2009, 15, 1155-1163.
- 32. Berendsen, H. J. C.; van der Spoel, D.; van Drunen, R. Comput. Phys. Commun. 1995, 91, 43-56.
- 33. Hess, B.; Kutzner, C.; van der Spoel, D.; Lindahl, E. J. Chem. Theory Comput. 2008, 4, 435.
- Hornak, V.; Abel, R.; Okur, A.; Strockbine, B.; Roitberg, A.; 34. Simmerling, C. Proteins 2006, 65, 712–725. Wang, J.; Wolf, R. M.; Caldwell, J. W.; Kollman, P. A.; Case, D.
- 35. A. J. Comput. Chem. 2004, 25, 1157-1174.
- D L Beveridge; and F M DiCapua Annu. Rev. Biophys. Biophys. 36. Chem. 1989, 18, 431-492.

, CC